Skip to main content

Table 1 Demographic and clinical features of study population

From: The frequency of and risk factors for osteoporosis in Korean patients with rheumatoid arthritis

 

Total

Osteoporosis

Osteopenia

Normal

p

(N = 1322)

(N = 619)

(N = 582)

(N = 121)

Age

61.2 ± 8.2

63.7 ± 8.2

59.8 ± 7.3

55.1 ± 6.6

<0.001

BMI (kg/m2)

22.9 ± 3.1

22.0 ± 3.2

23.4 ± 2.9

24.7 ± 3.3

<0.001

Disease duration (yrs)

12.1 ± 9.9

13.9 ± 10.6

10.9 ± −9.3

9.1 ± −8.7

<0.001

Previous fracture (N, %)

 Vertebrae

40 (3.0)

23 (1.7)

17 (1.3)

0 (0.0)

0.090

 Femur

24 (1.8)

19 (1.4)

5 (0.4)

0 (0.0)

0.004

 Wrist

66 (5.0)

38 (2.9)

27 (2.0)

1 (0.1)

0.042

 Upper arm

16 (1.2)

11 (0.8)

5 (0.4)

0 (0.0)

0.154

 Othersa

171 (12.9)

95 (7.2)

65 (74.9)

11 (0.8)

0.041

Use of GC (N, %)

1027 (77.7)

498 (80.5)

439 (75.4)

90 (74.4)

0.074

Current dose of GC (mg/day)

4.3 ± 2.5

4.4 ± 2.7

4.2 ± 2.4

4.4 ± 2.1

0.581

Cumulative dose of GC (g*mo)b

5.4 ± 7.0

6.7 ± 7.7

4.4 ± 6.4

3.6 ± 6.1

<0.001

HAQ (0–3)

0.9 (1.0)

1.0 (1.1)

0.8 (0.9)

0.6 (0.9)

<0.001

DAS28-ESR

4.0 (1.8)

3.9 (1.9)

4.0 (1.8)

3.8 (1.5)

0.120

ESR (mm/h)

26.0 (32.0)

25.0 (32.0)

28.0 (33.0)

24.0 (27.0)

0.240

CRP (mg/dL)

0.3 (0.8)

0.3 (0.8)

0.3 (0.9)

0.2 (0.5)

0.058

RF, positivity (N, %)

1158 (87.7)

545 (88.2)

510 (87.6)

103 (85.1)

0.644

ACPA, positivity (N, %)

899 (84.3)

395 (83.5)

418 (85.5)

86 (81.9)

0.551

  1. Values shown are median (interquartile range), mean ± standard deviation and frequency (percentage)
  2. BMI bone mass index, BMD bone mineral density, GC glucocorticoid, HAQ health assessment questionnaire, DAS 28-ESR Disease Activity Score 28 using ESR, ESR erythrocyte sedimentation rate, CRP C-reactive protein, RF rheumatoid factor, ACPA anti-cyclic-citrullinated protein antibody
  3. aNasal bone, clavicle, shoulder, scapula, rib, hand, pelvic bone, ankle, feet, coccyx
  4. bDose of glucocorticoids according prednisolone × 30 × months/1000